Neil Littman, founder of Bioverge, is an early-stage investor focused on healthcare companies at the intersection of bio. See sector focus and contact routes.
Neil Littman, founder of Bioverge, is an early-stage investor focused on healthcare companies at the intersection of bio + tech, primarily targeting seed-stage ventures with a portfolio split of roughly 60% therapeutic biotech platforms (including cell and gene therapies) and 20–25% digital health/digital therapeutics. His distinctive thesis centers on modernizing healthcare from "bench-to-bedside" by leveraging technology to combat preventable chronic diseases and democratizing access to healthcare venture capital for individual investors. Notable portfolio companies include Notable Labs (oncology drug combination testing), Ligandal (gene therapy platform), Crowd Med (crowdsourced medical case solving), and Blue Mesa Health (digital therapeutics).
StartupFundraising tracks this investor record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in San Francisco.
Investors like Neil Littman · Full investor directory · Investor access · Company funding database